Ch14.18 antibody produced in CHO cells in relapsed or refractory stage 4 neuroblastoma patients: A SIOPEN phase 1 study

mAbs

Volumn 5, Issue 5, 2013, Pages 801-809

  Ladenstein, Ruth ^a   Weixler, Silke ^b   Baykan, Bianca ^h   Bleeke, Matthias ^h   Kunert, Renate ^c   Katinger, Dietmar ^d   Pribill, Ingrid ^a   Glander, Petra ^b   Bauer, Steffen ^b   Pistoia, Vito ^f   Michon, Jean ^g   Garaventa, Alberto ^e   Lode, Holger N ^h  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^d Polymun Scientific GmbH   (Austria)

^e G GASLINI INSTITUTE   (Italy)

^f Laboratory of Oncology   (Italy)

^g INSTITUT CURIE   (France)

^h UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Anti GD2; Ch14.18 CHO; Immunotherapy; Monoclonal antibody; Neuroblastoma

Indexed keywords

CH14.18 ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ALLERGIC REACTION; ANEMIA; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CHILD; CHO CELL; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN; HYPERTENSION; IN VIVO STUDY; INFECTION; LEUKOPENIA; MALE; NAUSEA; NEPHROTOXICITY; NEUROBLASTOMA; NEUTROPENIA; PAIN; PRESCHOOL CHILD; SCHOOL CHILD; SERUM SICKNESS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; URINE RETENTION; VOMITING;

ANTI GD2; CH14.18/CHO; IMMUNOTHERAPY; MONOCLONAL ANTIBODY; NEUROBLASTOMA;

ADOLESCENT; ANEMIA; ANIMALS; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; FEVER; HUMANS; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; MICE, INBRED STRAINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEUROBLASTOMA; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 84883875530     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.25215     Document Type: Article

References (30)

1. Zeng Y, Fest S, Kunert R, Katinger H, Pistoia V, Michon J, et al. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Mol Immunol 2005; 42:1311-9; PMID:15950727; http://dx.doi.org/10.1016/j. molimm.2004.12.018
2. Ladenstein R, Pötschger U, Siabalis D, Garaventa A, Bergeron C, Lewis IJ, et al. Dose finding study for the use of subcutaneous recombinant interleukin-2 to augment natural killer cell numbers in an outpatient setting for stage 4 neuroblastoma after megatherapy and autologous stem-cell reinfusion. J Clin Oncol 2011; 29:441-8; PMID:21149662; http://dx.doi. org/10.1200/JCO. 2009.23.5465
3. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al.; Children's Cancer Group. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999; 341:1165-73; PMID:10519894; http://dx.doi.org/10.1056/NEJM199910143411601
4. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10:317-27; PMID:20414205; http://dx.doi.org/10.1038/nri2744
5. Yang RK, Sondel PM. Anti-GD2 Strategy in the Treatment of Neuroblastoma. Drugs Future 2010; 35:665; PMID:21037966
6. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al.; Children's Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363:1324-34; PMID:20879881; http://dx.doi.org/10.1056/NEJMoa0911123
7. Svennerholm L, Boström K, Fredman P, Jungbjer B, Lekman A, Månsson JE, et al. Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord. Biochim Biophys Acta 1994; 1214:115-23; PMID:7918590; http://dx.doi.org/10.1016/0005-2760(94)90034-5
8. Mujoo K, Kipps TJ, Yang HM, Cheresh DA, Wargalla U, Sander DJ, et al. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res 1989; 49:2857-61; PMID:2720646
9. Mueller BM, Romerdahl CA, Gillies SD, Reisfeld RA. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol 1990; 144:1382-6; PMID:2303711
10. Cheung NK, Guo HF, Heller G, Cheung IY. Induction of Ab3 and Ab3' antibody was associated with longterm survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma. Clin Cancer Res 2000; 6:2653-60; PMID:10914706
11. Riethmüller G, Holz E, Schlimok G, Schmiegel W, Raab R, Höffken K, et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: sevenyear outcome of a multicenter randomized trial. J Clin Oncol 1998; 16:1788-94; PMID:9586892
12. Handgretinger R, Anderson K, Lang P, Dopfer R, Klingebiel T, Schrappe M, et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 1995; 31A:261-7; PMID:7718335; http://dx.doi. org/10.1016/0959-8049(94)00413-Y
13. Uttenreuther-Fischer MM, Huang CS, Yu AL. Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients. Cancer Immunol Immunother 1995; 41:331-8; PMID:8635190; http://dx.doi.org/10. 1007/BF01526552
14. Kushner BH, Kramer K, Cheung NK. Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol 2001; 19:4189-94; PMID:11709561
15. Cheung NK, Kushner BH, Cheung IY, Kramer K, Canete A, Gerald W, et al. Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol 1998; 16:3053-60; PMID:9738575
16. Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Niethammer D, et al. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol 2004; 22:3549-57; PMID:15337804; http://dx.doi.org/10.1200/JCO.2004.08.143
17. Borys MC, Dalal NG, Abu-Absi NR, Khattak SF, Jing Y, Xing Z, et al. Effects of culture conditions on N-glycolylneuraminic acid (Neu5Gc) content of a recombinant fusion protein produced in CHO cells. Biotechnol Bioeng 2010; 105:1048-57; PMID:20039310
18. Taylor RE, Gregg CJ, Padler-Karavani V, Ghaderi D, Yu H, Huang S, et al. Novel mechanism for the generation of human xeno-autoantibodies against the nonhuman sialic acid N-glycolylneuraminic acid. J Exp Med 2010; 207:1637-46; PMID:20624889; http://dx.doi. org/10.1084/jem.20100575
19. Shepherd AJ, Wilson NJ, Smith KT. Characterisation of endogenous retrovirus in rodent cell lines used for production of biologicals. Biologicals 2003; 31:251-60; PMID:14624795; http://dx.doi.org/10.1016/S1045-1056(03)00065-4
20. European Agency for the Evaluation of Medicinal Products. Guideline on comparability of medicinal products containing biotechnology-derived proteins as active substance: quality issues. 1-11 (2003).
21. Albertini MR, Gan J, Jaeger P, Hank JA, Storer B, Schell K, et al. Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma. J Immunother Emphasis Tumor Immunol 1996; 19:278-95; PMID:8877722; http://dx.doi.org/10.1097/00002371-199607000- 00004
22. Mueller BM, Reisfeld RA, Gillies SD. Serum halflife and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2. Proc Natl Acad Sci U S A 1990; 87:5702-5; PMID:2198570; http://dx.doi. org/10.1073/pnas.87.15.5702
23. Yu AL, Uttenreuther-Fischer MM, Huang CS, Tsui CC, Gillies SD, Reisfeld RA, et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol 1998; 16:2169-80; PMID:9626218
24. Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Klingebiel T, et al. Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer 2011; 11:21; PMID:21244693; http://dx.doi.org/10.1186/1471-2407-11-21
25. Yuki N, Yamada M, Tagawa Y, Takahashi H, Handa S. Pathogenesis of the neurotoxicity caused by anti-GD2 antibody therapy. J Neurol Sci 1997; 149:127-30; PMID:9171318; http://dx.doi.org/10.1016/S0022-510X(97)05390-2
26. rd, Vail E, Gillies SD, Handgretinger R, et al. Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia. Pain 2010; 149:135-42; PMID:20171010; http://dx.doi. org/10.1016/j.pain.2010.01.024
27. Ozkaynak MF, Sondel PM, Krailo MD, Gan J, Javorsky B, Reisfeld RA, et al. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. J Clin Oncol 2000; 18:4077-85; PMID:11118469
28. Johnson E, Dean SM, Sondel PM. Antibody-based immunotherapy in high-risk neuroblastoma. Expert Rev Mol Med 2007; 9:1-21; PMID:18081947; http://dx.doi.org/10.1017/S1462399407000518
29. Lewington V, Poetschger U, Boubaker A, Bar-Sever Z, Drake B, Staudenherz A, et al. The prognostic value of semi-quantitative 123I mIBG scintigraphy at diagnosis in high-risk neuroblastoma: Validation of the SIOPEN score method. J Clin Oncol 2011; 29; suppl;abstr 9511.
30. Lode HN, Schmidt M, Seidel D, Huebener N, Brackrock D, Bleeke M, et al. Vaccination with antiidiotype antibody ganglidiomab mediates a GD2- specific anti-neuroblastoma immune response. Cancer Immunol Immunother 2013; 62:999-1010; PMID:23591980; http://dx.doi.org/10.1007/s00262-013-1413-y